Annual share-based awards recognized in first quarter (as a percent)

[Table of Contents](#ib0ff9808fe764fdea19589324372f96b_7)Abbott Laboratories and SubsidiariesNotes to the Condensed Consolidated Financial StatementsSeptember 30, 2022(Unaudited)Note 13 — Segment Information (Continued)The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.  


|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|   |  | Net Sales to External Customers |  | Operating Earnings |
|  |  | Three Months Ended Sept. 30 |  | Nine MonthsEnded Sept. 30 |  | Three Months Ended Sept. 30 |  | Nine MonthsEnded Sept. 30 |
| (in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |   | 2021 |   | 2022 |   | 2021 |
| Established Pharmaceutical Products |  | $ | 1,326  |  |  | $ | 1,265  |  |  | $ | 3,696  |  |  | $ | 3,515  |  |  | $ | 331  |  |  | $ | 293  |  |  | $ | 831  |  |  | $ | 682  |  |
| Nutritional Products |  | 1,795  |  |  | 2,108  |  |  | 5,642  |  |  | 6,252  |  |  | 69  |  |  | 431  |  |  | 550  |  |  | 1,388  |  |
| Diagnostic Products |  | 3,671  |  |  | 3,912  |  |  | 13,279  |  |  | 11,173  |  |  | 1,352  |  |  | 1,652  |  |  | 5,631  |  |  | 4,429  |  |
| Medical Devices |  | 3,615  |  |  | 3,632  |  |  | 10,937  |  |  | 10,618  |  |  | 1,039  |  |  | 1,160  |  |  | 3,272  |  |  | 3,375  |  |
| Total Reportable Segments |  | 10,407  |  |  | 10,917  |  |  | 33,554  |  |  | 31,558  |  |  | 2,791  |  |  | 3,536  |  |  | 10,284  |  |  | 9,874  |  |
| Other  |  | 3  |  |  | 11  |  |  | 8  |  |  | 49  |  |  |  |  |  |  |  |  |  |
| Net sales |  | $ | 10,410  |  |  | $ | 10,928  |  |  | $ | 33,562  |  |  | $ | 31,607  |  |  |  |  |  |  |  |  |  |
| Corporate functions and benefit plan costs |  |  |  |  |  |  |  |  |  | (115) |  |  | (204) |  |  | (352) |  |  | (450) |  |
| Net interest expense  |  |  |  |  |  |  |  |  |  | (86) |  |  | (123) |  |  | (309) |  |  | (370) |  |
| Share-based compensation (a)  |  |  |  |  |  |  |  |  |  | (123) |  |  | (114) |  |  | (570) |  |  | (534) |  |
| Amortization of intangible assets |  |  |  |  |  |  |  |  |  | (498) |  |  | (520) |  |  | (1,517) |  |  | (1,533) |  |
| Other, net (b) |  |  |  |  |  |  |  |  |  | (211) |  |  | (82) |  |  | (550) |  |  | (1,103) |  |
| Earnings before taxes |  |  |  |  |  |  |  |  |  | $ | 1,758  |  |  | $ | 2,493  |  |  | $ | 6,986  |  |  | $ | 5,884  |  |

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |
| (a) | Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.  |



|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |
| (b) | Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&D intangible assets. Other, net for the three and nine months ended September 30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September 30, 2021 also includes costs related to certain litigation. |

21
